Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) earlier this week outlined a major commercial milestone after signing a non-binding term sheet with a leading publicly listed Middle Eastern ...
Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) ...
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
At close: 4 February at 4:00:00 pm GMT-5 ...
Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...
Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data analysis expected in Q1 2025Additional ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Research reports are not currently available for RECEF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results